Healthcare Industry Reports

[danrobertsonrb-blog]

Menopausal Hot Flashes Global Clinical Trials Review, H2, 2015

Menopausal Hot Flashes Global Clinical Trials Review, H2, 2015 provides an overview of Menopausal Hot Flashes clinical trials scenario. This report provides top line data relating to the clinical trials on Menopausal Hot Flashes. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Enquiry about report: http://www.researchbeam.com/menopausal-hot-flashes-global-clinical-trials-review-h2-2015-market/enquire-about-report

 Scope

 - The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

 Table of Content

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Menopausal Hot Flashes to Women's Health Clinical Trials 15

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Menopausal Hot Flashes to Women's Health Clinical Trials 19

Clinical Trials by Phase in E7 Countries 21

Clinical Trials in E7 Countries by Trial Status 22

Clinical Trials by Phase 23

In Progress Trials by Phase 24

Clinical Trials by Trial Status 25

Clinical Trials by End Point Status 26

Subjects Recruited Over a Period of Time 27

Clinical Trials by Sponsor Type 28

Prominent Sponsors 29

Top Companies Participating in Menopausal Hot Flashes Therapeutics Clinical Trials 31

Prominent Drugs 33

Latest Clinical Trials News on Menopausal Hot Flashes 34

Sep 23, 2015: Euroscreen launches Phase 2 clinical trial with ESN364 as the first and unique non-hormonal causal treatment for menopausal Hot Flashes 34

Clinical Trial Profile Snapshots 35

Appendix 94

Abbreviations 94

Definitions 94

Research Methodology 95

Secondary Research 95

About GlobalData 96

Contact Us 96

Disclaimer 96

Source 97

 List of Tables

Menopausal Hot Flashes Therapeutics, Global, Clinical Trials by Region, 2015* 6

Menopausal Hot Flashes Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Menopausal Hot Flashes Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Menopausal Hot Flashes Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10

Menopausal Hot Flashes Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11

Menopausal Hot Flashes Therapeutics Clinical Trials, North America, Top Countries, 2015* 12

Menopausal Hot Flashes Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13

Menopausal Hot Flashes Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14

Proportion of Menopausal Hot Flashes to Women's Health Clinical Trials, G7 Countries (%), 2015* 16

Menopausal Hot Flashes Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17

Menopausal Hot Flashes Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18

Proportion of Menopausal Hot Flashes to Women's Health Clinical Trials, E7 Countries (%), 2015* 20

Menopausal Hot Flashes Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21

Menopausal Hot Flashes Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 22

Menopausal Hot Flashes Therapeutics, Global, Clinical Trials by Phase, 2015* 23

Menopausal Hot Flashes Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 24

Menopausal Hot Flashes Therapeutics, Global, Clinical Trials by Trial Status, 2015* 25

Menopausal Hot Flashes Therapeutics Clinical Trials, Global, by End Point Status, 2015* 26

Menopausal Hot Flashes Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27

Menopausal Hot Flashes Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 28

Menopausal Hot Flashes Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30

Menopausal Hot Flashes Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32

Menopausal Hot Flashes Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33

 List of Figures

Menopausal Hot Flashes Therapeutics, Global, Clinical Trials by Region (%), 2015* 6

Menopausal Hot Flashes Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7

Menopausal Hot Flashes Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Menopausal Hot Flashes Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10

Menopausal Hot Flashes Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11

Menopausal Hot Flashes Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12

Menopausal Hot Flashes Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13

Menopausal Hot Flashes Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14

Proportion of Menopausal Hot Flashes to Women's Health Clinical Trials, G7 Countries (%), 2015* 15

Menopausal Hot Flashes Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17

Menopausal Hot Flashes Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18

Proportion of Menopausal Hot Flashes to Women's Health Clinical Trials, E7 Countries (%), 2015* 19

Menopausal Hot Flashes Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21

Menopausal Hot Flashes Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 22

Menopausal Hot Flashes Therapeutics, Global, Clinical Trials by Phase (%), 2015* 23

Menopausal Hot Flashes Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 24

Menopausal Hot Flashes Therapeutics, Global, Clinical Trials by Trial Status, 2015* 25

Menopausal Hot Flashes Therapeutics Clinical Trials, Global, by End Point Status, 2015* 26

Menopausal Hot Flashes Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27

Menopausal Hot Flashes Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 28

Menopausal Hot Flashes Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 29

Menopausal Hot Flashes Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31

Menopausal Hot Flashes Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33

GlobalData Methodology 95

Source: http://www.researchbeam.com/menopausal-hot-flashes-global-clinical-trials-review-h2-2015-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook

"Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook" discusses all gene therapies under the broad criteria of genetic material introduced to the cell for a therapeutic purpose. It includes not only the insertion of a gene into the cell for expression, but also gene silencing with RNA interference (RNAi) and antisense RNA, aptamers (DNA or RNA polymers which bind to a protein target), and oncolytic viruses.

Enquiry about report: http://www.researchbeam.com/gene-therapies-a-diverse-range-of-technologies-with-a-promising-long-term-outlook-market/enquire-about-report

 Gene therapies have been in development in humans for 25 years, and a number of products have begun to enter the pharmaceutical market. However, due to various challenges and clinical trial setbacks, progress in developing this technology and achieving suitability for commercial usage has been slow. Gene therapies only account for a marginal market share and many efficacy and safety concerns remain unaddressed. However, the pipeline is robust; 906 pipeline gene therapies are currently in development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage. However, there are currently 23 gene therapy programs in Phase III development and two at the Pre-registration stage. This indicates that although gene therapies are beginning to reach the market after two decades of research in humans, the majority remain in relatively early development.

This CBR report provides a comprehensive view of the clinical, R&D, commercial and competitive landscape of Gene Therapy, and assesses key developments in delivery vector technology, and challenges and advances associated with the production of such vectors.

 Scope

Despite 25 years of clinical research, only a few gene therapies of all types have reached the market globally, and none have achieved strong clinical or commercial success

Why do gene therapies still occupy only a minimal market share in their respective indications?

What can be learned from the gene therapies that have already reached the market?

A number of different viral and non-viral vector types are currently in development for the delivery of gene therapies

What are the relative advantages and disadvantages of each vector type and which hold the most promise?

What proportion of the overall gene therapy R&D pipeline is occupied by each vector type?

The current pipeline for gene therapies is diverse in terms of the approaches and vectors covered; 50% are gene silencing therapies, while 31% involve the insertion of a functional gene

In which therapy areas is there the highest level of R&D activity for gene therapies?

At which stage of development does the majority of pipeline gene therapies reside?

What is the proportion of the pipeline occupied by each intervention and vector type overall?

A number of companies are currently actively developing pipeline gene therapies, including private, public and institutional enterprises

How do gene therapies fit into the overall portfolios of these companies?

What is the level of involvement in gene therapy research from the top 20 Big Pharma companies?

 Table of Content

Gene Therapy Overview

Types of Gene Therapy

Types of Intervention

Types of Vector

Currently Approved Gene Therapies

Glybera (alipogene tiparvovec)

Kynamro (mipomersen)

Macugen (pegaptanib)

Vitravene (fomivirsen)

Gendicine (rAd-p53)

Oncorine (rAd5-H101)

Neovasculgen (Pl-VEGF165)

Gene Therapy Production Strategies

Production of Viral Vectors

Case Study: Challenges in the Manufacture of AAV Vectors

Challenges to Gene Therapy Development

Gene Therapy Pipeline

Gene Therapy Pipeline by Therapy Area and Stage of Development

Gene Therapy Pipeline by Intervention and Vector Type

Company Positioning

Companies by Therapy Area

Companies by Stage of Development

Companies by Intervention Type

Companies by Vector Type

Conclusion

Appendix

References

About GBI Research

Source: http://www.researchbeam.com/gene-therapies-a-diverse-range-of-technologies-with-a-promising-long-term-outlook-market

 About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Clinical Chemistry Analyzers - Medical Devices Pipeline Assessment, 2015

Clinical Chemistry Analyzers - Medical Devices Pipeline Assessment, 2015 provides an overview of Clinical Chemistry Analyzers currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Clinical Chemistry Analyzers pipeline products.

Enquiry about report: http://www.researchbeam.com/clinical-chemistry-analyzers-medical-devices-pipeline-assessment-2015-market/enquire-about-report

Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 7

2 Introduction 8

2.1 Clinical Chemistry Analyzers Overview 8

3 Products under Development 9

3.1 Clinical Chemistry Analyzers - Pipeline Products by Stage of Development 9

3.2 Clinical Chemistry Analyzers - Pipeline Products by Segment 10

3.3 Clinical Chemistry Analyzers - Pipeline Products by Territory 11

3.4 Clinical Chemistry Analyzers - Pipeline Products by Regulatory Path 12

3.5 Clinical Chemistry Analyzers - Pipeline Products by Estimated Approval Date 13

3.6 Clinical Chemistry Analyzers - Ongoing Clinical Trials 14

4 Clinical Chemistry Analyzers - Pipeline Products under Development by Companies 15

4.1 Clinical Chemistry Analyzers Companies - Pipeline Products by Stage of Development 15

4.2 Clinical Chemistry Analyzers - Pipeline Products by Stage of Development 17

5 Clinical Chemistry Analyzers Companies and Product Overview 19

5.1 Abingdon Health Ltd Company Overview 19

5.1.1 Abingdon Health Ltd Pipeline Products & Ongoing Clinical Trials Overview 19

5.2 Agenix Limited Company Overview 21

5.2.1 Agenix Limited Pipeline Products & Ongoing Clinical Trials Overview 21

5.3 Analyticon Biotechnologies AG Company Overview 22

5.3.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 22

5.4 Atonomics A/S Company Overview 25

5.4.1 Atonomics A/S Pipeline Products & Ongoing Clinical Trials Overview 25

5.5 Attophotonics Biosciences GmbH Company Overview 26

5.5.1 Attophotonics Biosciences GmbH Pipeline Products & Ongoing Clinical Trials Overview 26

5.6 Aviv Biomedical, Inc. Company Overview 27

5.6.1 Aviv Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 27

5.7 Beacon Biotechnology Company Overview 28

5.7.1 Beacon Biotechnology Pipeline Products & Ongoing Clinical Trials Overview 28

5.8 Becton, Dickinson and Company Company Overview 29

5.8.1 Becton, Dickinson and Company Pipeline Products & Ongoing Clinical Trials Overview 29

5.9 Bio-Alternative Medical Devices Ltd Company Overview 31

5.9.1 Bio-Alternative Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

5.10 bioMerieux S.A. Company Overview 33

5.10.1 bioMerieux S.A. Pipeline Products & Ongoing Clinical Trials Overview 33

5.11 CAIR Technologies Inc. Company Overview 35

5.11.1 CAIR Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 35

5.12 Clinical Sensors, Inc. Company Overview 36

5.12.1 Clinical Sensors, Inc. Pipeline Products & Ongoing Clinical Trials Overview 36

5.13 Curetis AG Company Overview 37

5.13.1 Curetis AG Pipeline Products & Ongoing Clinical Trials Overview 37

5.14 Daxor Corporation Company Overview 40

5.14.1 Daxor Corporation Pipeline Products & Ongoing Clinical Trials Overview 40

5.15 EMERGENT DETECTION INC Company Overview 41

5.15.1 EMERGENT DETECTION INC Pipeline Products & Ongoing Clinical Trials Overview 41

5.16 Exact Sciences Corporation Company Overview 42

5.16.1 Exact Sciences Corporation Pipeline Products & Ongoing Clinical Trials Overview 42

5.17 GenPrime Incorporated Company Overview 44

5.17.1 GenPrime Incorporated Pipeline Products & Ongoing Clinical Trials Overview 44

5.18 Hansjorg Wyss Institute for Biologically Inspired Engineering Company Overview 45

5.18.1 Hansjorg Wyss Institute for Biologically Inspired Engineering Pipeline Products & Ongoing Clinical Trials Overview 45

5.19 Holomic LLC Company Overview 46

5.19.1 Holomic LLC Pipeline Products & Ongoing Clinical Trials Overview 46

5.20 Illumina, Inc. Company Overview 47

5.20.1 Illumina, Inc. Pipeline Products & Ongoing Clinical Trials Overview 47

5.21 i-SENS, Inc. Company Overview 49

5.21.1 i-SENS, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49

5.22 IV Diagnostics, Inc. Company Overview 50

5.22.1 IV Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50

5.23 National Institute of Biomedical Imaging and Bioengineering Company Overview 51

5.23.1 National Institute of Biomedical Imaging and Bioengineering Pipeline Products & Ongoing Clinical Trials Overview 51

5.24 NeuMoDx Molecular, Inc Company Overview 52

5.24.1 NeuMoDx Molecular, Inc Pipeline Products & Ongoing Clinical Trials Overview 52

5.25 Nova Biomedical Corporation Company Overview 53

5.25.1 Nova Biomedical Corporation Pipeline Products & Ongoing Clinical Trials Overview 53

5.26 Renishaw Plc Company Overview 55

5.26.1 Renishaw Plc Pipeline Products & Ongoing Clinical Trials Overview 55

5.27 Rheonix, Inc. Company Overview 57

5.27.1 Rheonix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 57

5.28 Roche Diagnostics International Ltd. Company Overview 59

5.28.1 Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview 59

5.29 Samsung Electronics Co., Ltd. Company Overview 60

5.29.1 Samsung Electronics Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 60

5.30 Sekisui Diagnostics, LLC. Company Overview 62

5.30.1 Sekisui Diagnostics, LLC. Pipeline Products & Ongoing Clinical Trials Overview 62

5.31 SenGenix, Inc. Company Overview 63

5.31.1 SenGenix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63

5.32 Shenzhen Genius Electronics Co., Ltd. Company Overview 64

5.32.1 Shenzhen Genius Electronics Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 64

5.33 The Hong Kong University of Science and Technology Company Overview 65

5.33.1 The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 65

5.34 Thermal Gradient, Inc. Company Overview 66

5.34.1 Thermal Gradient, Inc. Pipeline Products & Ongoing Clinical Trials Overview 66

5.35 Verifica-BG, Inc. Company Overview 67

5.35.1 Verifica-BG, Inc. Pipeline Products & Ongoing Clinical Trials Overview 67

6 Clinical Chemistry Analyzers- Recent Developments 68

7 Appendix 113

7.1 Methodology 113

7.2 About GlobalData 115

7.3 Contact Us 115

7.4 Disclaimer 116

 Source: http://www.researchbeam.com/clinical-chemistry-analyzers-medical-devices-pipeline-assessment-2015-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Auto-Immune Diseases - Medical Devices Pipeline Assessment, 2015

Auto-Immune Diseases Medical Devices Pipeline Assessment, 2015 provides an overview of Auto-Immune Diseases currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Auto-Immune Diseases pipeline products.

Enquiry about report: http://www.researchbeam.com/auto-immune-diseases-medical-devices-pipeline-assessment-2015-market/enquire-about-report

 Scope

Extensive coverage of the Auto-Immune Diseases under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Auto-Immune Diseases and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

 Table of Contents

1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 18

2 Introduction 19

2.1 Auto-Immune Diseases Overview 19

3 Products under Development 20

3.1 Auto-Immune Diseases - Pipeline Products by Stage of Development 20

3.2 Auto-Immune Diseases - Pipeline Products by Territory 21

3.3 Auto-Immune Diseases - Pipeline Products by Regulatory Path 22

3.4 Auto-Immune Diseases - Pipeline Products by Estimated Approval Date 23

4 Auto-Immune Diseases - Pipeline Products under Development by Companies 24

4.1 Auto-Immune Diseases Companies - Pipeline Products by Stage of Development 24

4.2 Auto-Immune Diseases - Pipeline Products by Stage of Development 28

5 Auto-Immune Diseases Companies and Product Overview 35

5.1 Adaptive Biotechnologies Corporation Company Overview 35

5.1.1 Adaptive Biotechnologies Corporation Pipeline Products & Ongoing Clinical Trials Overview 35

5.2 Agena Bioscience, Inc Company Overview 36

5.2.1 Agena Bioscience, Inc Pipeline Products & Ongoing Clinical Trials Overview 36

5.3 Albert-Ludwigs-Universitat Freiburg Company Overview 37

5.3.1 Albert-Ludwigs-Universitat Freiburg Pipeline Products & Ongoing Clinical Trials Overview 37

5.4 Alere Inc. Company Overview 40

5.4.1 Alere Inc. Pipeline Products & Ongoing Clinical Trials Overview 40

5.5 Amarantus Bioscience Holdings, Inc. Company Overview 43

5.5.1 Amarantus Bioscience Holdings, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43

5.6 Amdix B.V. Company Overview 46

5.6.1 Amdix B.V. Pipeline Products & Ongoing Clinical Trials Overview 46

5.7 Analyticon Biotechnologies AG Company Overview 47

5.7.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 47

5.8 apDia n.v. Company Overview 48

5.8.1 apDia n.v. Pipeline Products & Ongoing Clinical Trials Overview 48

5.9 Autoimmune Technologies, LLC Company Overview 49

5.9.1 Autoimmune Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 49

5.10 Beckman Coulter, Inc. Company Overview 55

6 Auto-Immune Diseases- Recent Developments 263

7 Appendix 292

7.1 Methodology 292

7.2 About GlobalData 294

7.3 Contact Us 295

7.4 Disclaimer 295

 Source: http://www.researchbeam.com/auto-immune-diseases-medical-devices-pipeline-assessment-2015-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Electrophysiology Devices - Medical Devices Pipeline Assessment, 2015

Electrophysiology Devices - Medical Devices Pipeline Assessment, 2015 provides an overview of Electrophysiology Devices currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Electrophysiology Devices pipeline products.

Enquiry about report: http://www.researchbeam.com/electrophysiology-devices-medical-devices-pipeline-assessment-2015-market/enquire-about-report

 Scope

- Extensive coverage of the Electrophysiology Devices under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Electrophysiology Devices and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

 Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 11

2 Introduction 12

2.1 Electrophysiology Devices Overview 12

3 Products under Development 14

3.1 Electrophysiology Devices - Pipeline Products by Stage of Development 14

3.2 Electrophysiology Devices - Pipeline Products by Segment 15

3.3 Electrophysiology Devices - Pipeline Products by Territory 16

3.4 Electrophysiology Devices - Pipeline Products by Regulatory Path 18

3.5 Electrophysiology Devices - Pipeline Products by Estimated Approval Date 19

3.6 Electrophysiology Devices - Ongoing Clinical Trials 20

4 Electrophysiology Devices - Pipeline Products under Development by Companies 21

4.1 Electrophysiology Devices Companies - Pipeline Products by Stage of Development 21

4.2 Electrophysiology Devices - Pipeline Products by Stage of Development 24

5 Electrophysiology Devices Companies and Product Overview 27

5.1 AblaCor Medical Corporation Company Overview 27

5.1.1 AblaCor Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 27

5.2 Acutus Medical, Inc. Company Overview 28

5.2.1 Acutus Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28

5.3 Advanced Cardiac Therapeutics, Inc. Company Overview 30

5.3.1 Advanced Cardiac Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 30

5.4 AFfix Medical Ltd. Company Overview 31

5.4.1 AFfix Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 31

5.5 Apama Medical, Inc. Company Overview 34

5.5.1 Apama Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34

5.6 AtriCure, Inc. Company Overview 35

5.6.1 AtriCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35

5.7 Baylor College of Medicine Company Overview 41

5.7.1 Baylor College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 41

5.8 Biosense Webster, Inc. Company Overview 43

5.8.1 Biosense Webster, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43

5.9 BioSig Technologies, Inc. Company Overview 47

5.9.1 BioSig Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 47

5.10 BioTex, Inc. Company Overview 48

5.10.1 BioTex, Inc. Pipeline Products & Ongoing Clinical Trials Overview 48

5.11 Boston Scientific Corporation Company Overview 50

5.11.1 Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 50

5.12 C. R. Bard, Inc. Company Overview 65

5.12.1 C. R. Bard, Inc. Pipeline Products & Ongoing Clinical Trials Overview 65

5.13 Cardima, Inc. (Inactive) Company Overview 69

5.13.1 Cardima, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 69

5.14 CardioFocus, Inc. Company Overview 72

5.14.1 CardioFocus, Inc. Pipeline Products & Ongoing Clinical Trials Overview 72

5.15 CardioNova Ltd. Company Overview 76

5.15.1 CardioNova Ltd. Pipeline Products & Ongoing Clinical Trials Overview 76

5.16 CathEffects LLC Company Overview 77

5.16.1 CathEffects LLC Pipeline Products & Ongoing Clinical Trials Overview 77

5.17 CathRx Ltd Company Overview 78

5.17.1 CathRx Ltd Pipeline Products & Ongoing Clinical Trials Overview 78

5.18 Cordis Corporation Company Overview 82

5.18.1 Cordis Corporation Pipeline Products & Ongoing Clinical Trials Overview 82

5.19 CoRepair, Inc Company Overview 84

5.19.1 CoRepair, Inc Pipeline Products & Ongoing Clinical Trials Overview 84

5.20 CyberHeart Incorporated Company Overview 85

5.20.1 CyberHeart Incorporated Pipeline Products & Ongoing Clinical Trials Overview 85

5.21 Epicardial Technologies Inc Company Overview 87

5.21.1 Epicardial Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 87

5.22 FocusStart Orthosensors Company Overview 88

5.22.1 FocusStart Orthosensors Pipeline Products & Ongoing Clinical Trials Overview 88

5.23 Fundacion para la Investigacion Biomedica del Hospital Gregorio Maranon Company Overview 89

5.23.1 Fundacion para la Investigacion Biomedica del Hospital Gregorio Maranon Pipeline Products & Ongoing Clinical Trials Overview 89

5.24 Hansen Medical, Inc. Company Overview 90

5.24.1 Hansen Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 90

5.25 Imricor Medical Systems, Inc. Company Overview 97

5.25.1 Imricor Medical Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 97

5.26 Interventional Imaging, Inc. Company Overview 102

5.26.1 Interventional Imaging, Inc. Pipeline Products & Ongoing Clinical Trials Overview 102

5.27 Iowa Approach Inc. Company Overview 103

5.27.1 Iowa Approach Inc. Pipeline Products & Ongoing Clinical Trials Overview 103

5.28 Maestro Heart SA Company Overview 106

5.28.1 Maestro Heart SA Pipeline Products & Ongoing Clinical Trials Overview 106

5.29 Mayo Clinic. Company Overview 107

5.29.1 Mayo Clinic. Pipeline Products & Ongoing Clinical Trials Overview 107

5.30 MC10, Inc. Company Overview 108

5.30.1 MC10, Inc. Pipeline Products & Ongoing Clinical Trials Overview 108

5.31 Medicalgorithmics S.A. Company Overview 110

5.31.1 Medicalgorithmics S.A. Pipeline Products & Ongoing Clinical Trials Overview 110

5.32 Medispec LTD Company Overview 111

5.32.1 Medispec LTD Pipeline Products & Ongoing Clinical Trials Overview 111

5.33 Medlumics S.L. Company Overview 113

5.33.1 Medlumics S.L. Pipeline Products & Ongoing Clinical Trials Overview 113

5.34 Medtronic plc Company Overview 115

5.34.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 115

5.35 MedWaves Incorporated Company Overview 120

5.35.1 MedWaves Incorporated Pipeline Products & Ongoing Clinical Trials Overview 120

5.36 MicroPort Scientific Corporation Company Overview 122

5.36.1 MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 122

5.37 MRI Interventions, Inc Company Overview 125

5.37.1 MRI Interventions, Inc Pipeline Products & Ongoing Clinical Trials Overview 125

5.38 nContact, Inc. Company Overview 127

5.38.1 nContact, Inc. Pipeline Products & Ongoing Clinical Trials Overview 127

5.39 North Carolina State University Company Overview 131

5.39.1 North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview 131

5.40 Northwestern University Company Overview 132

5.40.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 132

5.41 Philips Healthcare Company Overview 134

5.41.1 Philips Healthcare Pipeline Products & Ongoing Clinical Trials Overview 134

5.42 SCR, Inc. Company Overview 136

5.42.1 SCR, Inc. Pipeline Products & Ongoing Clinical Trials Overview 136

5.43 St. Jude Medical, Inc. Company Overview 137

5.43.1 St. Jude Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 137

5.44 Stereotaxis, Inc. Company Overview 144

5.44.1 Stereotaxis, Inc. Pipeline Products & Ongoing Clinical Trials Overview 144

5.45 Strategic Polymer Sciences, Inc Company Overview 147

5.45.1 Strategic Polymer Sciences, Inc Pipeline Products & Ongoing Clinical Trials Overview 147

5.46 The Cleveland Clinic Foundation Company Overview 148

5.46.1 The Cleveland Clinic Foundation Pipeline Products & Ongoing Clinical Trials Overview 148

5.47 University of Rochester Company Overview 150

5.47.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 150

5.48 University of Texas Medical Branch at Galveston Company Overview 152

5.48.1 University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview 152

5.49 Vimecon GmbH Company Overview 154

5.49.1 Vimecon GmbH Pipeline Products & Ongoing Clinical Trials Overview 154

5.50 Vivonics, Inc. Company Overview 156

5.50.1 Vivonics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 156

5.51 Voyage Medical Company Overview 159

5.51.1 Voyage Medical Pipeline Products & Ongoing Clinical Trials Overview 159

6 Electrophysiology Devices- Recent Developments 161

7 Appendix 223

7.1 Methodology 223

7.2 About GlobalData 225

7.3 Contact Us 226

7.4 Disclaimer 226

 Reasons to buy

The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Electrophysiology Devices under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the products current stage of development, territory and estimated launch date

Source: http://www.researchbeam.com/electrophysiology-devices-medical-devices-pipeline-assessment-2015-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 85-95% of all diabetics have T2DM.

Enquiry about report: http://www.researchbeam.com/type-2-diabetes-mellitus-therapeutics-in-asia-pacific-to-2021-increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-robust-growth-market/enquire-about-report

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

 Scope

 The current T2DM in the Asia-Pacific (APAC) market contains novel products, including Jardiance - a SGLT-2 inhibitor; Victoza - a GLP-1 receptor agonist; and Galvus - a DPP-4 inhibitor.

- What are the competitive advantages of the existing novel drugs?

With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes, in comparison to currently marketed products and combination therapies.

- Which classes of novel drugs are most prominent within the pipeline?

- Is there strong potential for the pipeline to address unmet needs within the T2DM market?

Analysis of clinical trials, since 2006, identified that the failure rates of T2DM molecules were highest in Phase II, at 54%, with the overall attrition rate for T2DM at 82.6%.

- How do failure rates vary by product stage of development, molecule type, and mechanism of action?

- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

Over the 2014-2021 forecast period, the T2DM therapeutics in the APAC markets is expected to increase in value at a CAGR of 7.7%, from $6.07 billion to over $10.2 billion.

- Which markets make the most significant contribution to the current market size?

- What are the epidemiology trends in these markets?

- Will new market entrants lead to substantial changes in annual therapy costs?

- How will different treatment usage patterns impact growth in the four assessed Asia-Pacific markets?

Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth, over the forecast period, despite generic sales erosion resulting from patent expirations.

- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?

- Which patent expirations will have the most significant impact on the market?

 Table Of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Introduction 9

2.1 Disease Overview 9

2.2 Classification 9

3 Marketed Products 43

3.1 Overview 43

3.2 Biguanides 44

4 Pipeline 70

4.1 Overview 70

4.2 Pipeline Distribution by Stage of Development, Molecule Type and Program Type 71

5 Market Forecast to 2021 99

5.1 Geographical Markets 99

5.2 Asia-Pacific Markets 99

6 Strategic Consolidations 113

6.1 Licensing Deals 113

6.2 Co-development Deals 120

7 Appendix 129

7.1 All Pipeline Drugs by Phase of Development 129

7.2 Market Forecasts to 2021 146

Reasons to buy

 This report will enable you to -

- Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.

- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.

- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.

- Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.

- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.

- Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, and Japan.

- Discover trends in licensing and co-development deals concerning T2DM products and identify the major strategic consolidations that have shaped the commercial landscape.

Source: http://www.researchbeam.com/type-2-diabetes-mellitus-therapeutics-in-asia-pacific-to-2021-increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-robust-growth-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Switchgear Market for Power Industry, Update 2015

Switchgear Market for Power Industry, Update 2015 - Global Market Size, Equipment Market Share and Key Country Analysis to 2020 is the latest market analysis report, the industry analysis specialists that offer comprehensive information and understanding of the power industry. The report gives detailed information on the current switchgear market, focusing on key countries, as well as covering the global scenario. The report analyzes the annual revenues and share of the various voltage levels for the seven key countries in the market. The market shares for the key players in different voltage segments of each country have been provided. The drivers and restraints of the market of the global market as well as the specific countries are also provided. The report is built using data and information sourced from primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Enquiry about report: http://www.researchbeam.com/switchgear-for-power-industry-update-2015-global-size-equipment-share-and-key-country-analysis-to-2020-market/enquire-about-report

 Scope

 The report analyses global switchgear market. It includes -

- An in-depth analysis of the switchgear market in US, Canada, China, India, the UK, Italy and Saudi Arabia.

- Covering annual market size for the period from 2006 to 2020 for switchgear.

- Market share of players/leading players for switchgears in different voltage segmnet in 2014.

- It discusses the key drivers and restraints impacting the switchgear market at global and country level.

 Table of Contents

1 Table of Contents 4

1.1 List of Tables 10

1.2 List of Figures 13

2 Introduction 17

2.1 Switchgear 17

2.1.1 High-Voltage Switchgear 18

2.1.2 Medium-Voltage Switchgear 18

2.1.3 Low-Voltage Switchgear 18

2.2 GlobalData Report Guidance 19

3 Switchgear Market, Global 20

3.1 Transmission and Distribution Sector, Global, Overview 20

3.2 Switchgear Market, Global, Market Size, 2006-2020 26

4 Switchgear Market, US 31

4.1 Transmission and Distribution Sector, US, Overview 31

4.2 Switchgear Market, US, Market Size, 2006-2020 37

5 Switchgear Market, Canada 52

5.1 Transmission and Distribution Sector, Canada, Overview 52

5.2 Switchgear Market, Canada, Market Size, 2006-2020 55

6 Switchgear Market, China 69

6.1 Transmission and Distribution Sector, China, Overview 69

6.2 Switchgear Market, China, Market Size, 2006-2020 74

7 Switchgear Market, India 88

7.1 Transmission and Distribution Sector, India, Overview 88

7.2 Switchgear Market, India, Market Size, 2006-2020 94

8 Switchgear Market, UK 109

8.1 Transmission and Distribution Sector, UK, Overview 109

8.2 Switchgear Market, UK, Market Size, 2006-2020 113

9 Switchgear Market, Italy 127

9.1 Transmission and Distribution Sector, Italy, Overview 127

9.2 Switchgear Market, Italy, Market Size, 2006-2020 132

10 Switchgear Market, Saudi Arabia 146

10.1 Transmission and Distribution Sector, Saudi Arabia, Overview 146

10.2 Switchgear Market, Saudi Arabia, Market Size, 2006-2020 152

11 Appendix 165

11.1 Abbreviations 165

11.2 Bibliography 166

 Reasons to buy

 The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to -

- Facilitate decision making, by providing historical and forecast data on the revenue and volume for switchgear market

- Develop strategies based on the various market developments in the switchgear market

- Identify key partners and business development avenues, based on an understanding of the market movements of the major competitors in the switchgear market.

- Respond to your competitors business structure, strategy and prospects

Source: http://www.researchbeam.com/switchgear-for-power-industry-update-2015-global-size-equipment-share-and-key-country-analysis-to-2020-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Urine Analysis — Pipeline Review, 2015

Urine Analysis Pipeline Review, 2015 provides an overview of Urine Analysis products currently in pipeline stage.The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Urine Analysis pipeline products.

Enquiry about report: http://www.researchbeam.com/urine-analysis-pipeline-review-2015-market/enquire-about-report

 Scope

Extensive coverage of the Urine Analysis products under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Urine Analysis products and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

 Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Introduction 6

2.1 Urine Analysis Overview 6

3 Products under Development 7

3.1 Urine Analysis - Pipeline Products by Stage of Development 7

3.2 Urine Analysis - Pipeline Products by Segment 8

3.3 Urine Analysis - Pipeline Products by Territory 9

3.4 Urine Analysis - Pipeline Products by Regulatory Path 10

3.5 Urine Analysis - Pipeline Products by Estimated Approval Date 11

3.6 Urine Analysis - Ongoing Clinical Trials 12

4 Urine Analysis - Pipeline Products under Development by Companies 13

4.1 Urine Analysis Companies - Pipeline Products by Stage of Development 13

4.2 Urine Analysis - Pipeline Products by Stage of Development 14

5 Urine Analysis Companies and Product Overview 15

5.1 Analyticon Biotechnologies AG Company Overview 15

5.1.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 15

5.2 Arkray, Inc. Company Overview 17

5.2.1 Arkray, Inc. Pipeline Products & Ongoing Clinical Trials Overview 17

5.3 Biosense Technologies Pvt Ltd. Company Overview 19

5.3.1 Biosense Technologies Pvt Ltd. Pipeline Products & Ongoing Clinical Trials Overview 19

5.4 California Pacific Medical Center Research Institute Company Overview 22

5.4.1 California Pacific Medical Center Research Institute Pipeline Products & Ongoing Clinical Trials Overview 22

5.5 Erba Diagnostics, Inc. Company Overview 23

5.5.1 Erba Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23

5.6 Imagnus Biomedical Inc. Company Overview 25

5.6.1 Imagnus Biomedical Inc. Pipeline Products & Ongoing Clinical Trials Overview 25

5.7 Imperial College London Company Overview 26

5.7.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 26

5.8 IRIS International, Inc. Company Overview 27

5.8.1 IRIS International, Inc. Pipeline Products & Ongoing Clinical Trials Overview 27

5.9 LifeAssays AB Company Overview 28

5.9.1 LifeAssays AB Pipeline Products & Ongoing Clinical Trials Overview 28

5.10 Roche Diagnostics International Ltd. Company Overview 30

5.10.1 Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview 30

5.11 Scanadu HQ Company Overview 32

5.11.1 Scanadu HQ Pipeline Products & Ongoing Clinical Trials Overview 32

5.12 Shenzhen Genius Electronics Co., Ltd. Company Overview 33

5.12.1 Shenzhen Genius Electronics Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 33

5.13 Siemens Healthcare Diagnostics Inc. Company Overview 35

5.13.1 Siemens Healthcare Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 35

5.14 Stanford University Company Overview 36

5.14.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 36

5.15 Svenska Cellulosa Aktiebolaget Company Overview 37

5.15.1 Svenska Cellulosa Aktiebolaget Pipeline Products & Ongoing Clinical Trials Overview 37

5.16 Sysmex Corporation Company Overview 39

5.16.1 Sysmex Corporation Pipeline Products & Ongoing Clinical Trials Overview 39

5.17 Teco Diagnostics Company Overview 41

5.17.1 Teco Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 41

5.18 University of California, San Francisco Company Overview 42

5.18.1 University of California, San Francisco Pipeline Products & Ongoing Clinical Trials Overview 42

5.19 University of Kentucky Company Overview 44

5.19.1 University of Kentucky Pipeline Products & Ongoing Clinical Trials Overview 44

5.20 University of Maryland, Baltimore Company Overview 45

5.20.1 University of Maryland, Baltimore Pipeline Products & Ongoing Clinical Trials Overview 45

6 Urine Analysis- Recent Developments 46

7 Appendix 69

7.1 Methodology 69

7.2 About GlobalData 71

7.3 Contact Us 72

7.4 Disclaimer 72

 Source: http://www.researchbeam.com/urine-analysis-pipeline-review-2015-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Polyethylene Terephthalate (PET) Industry Outlook in Malaysia to 2019

Polyethylene Terephthalate (PET) Industry Outlook in Malaysia to 2019 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants, provides in-depth coverage of Malaysias PET industry and presents major market trends. The report covers Malaysias PET plants and presents installed capacity by production process and technology. It also gives historical and forecast market size, demand and production forecasts, end-use demand details, price trends, trade balance data, and company shares of the countrys leading PET producers to provide comprehensive coverage of all parameters of the PET industry.

Enquiry about report: http://www.researchbeam.com/polyethylene-terephthalate-pet-industry-outlook-in-malaysia-to-2019-size-company-share-price-trends-capacity-forecasts-of-all-active-and-planned-plants-market/enquire-about-report

 Scope

- PET industry supply scenario in Malaysia from 2005 to 2019, comprising plant capacity growth and installed plant capacity by production process and technology

- Detailed information of all active plants and planned PET projects in Malaysia with capacity forecasts to 2019 and additional details such as production process, technology, operator and equity

- PET industry market dynamics in Malaysia from 2005 to 2019, consisting of market size, demand and production outlook, demand by end-use sector, and average prices

- Trade balance data from 2005 to 2019, including import and export data and net exports and imports as a percentage of demand

- Company snapshots, including company overview, business description and information on current and upcoming PET plants

- Company capacity shares for key PET producers

 Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Malaysia Polyethylene Terephthalate (PET) Industry, Supply Scenario, 2005-2019 6

Malaysia Polyethylene Terephthalate (PET) Industry, Total Plant Capacity, 2005-2019 6

Malaysia Polyethylene Terephthalate (PET) Industry, Installed Plant Capacity by Production Process, 2014 13

Malaysia Polyethylene Terephthalate (PET) Industry, Installed Plant Capacity by Technology, 2014 13

Malaysia Polyethylene Terephthalate (PET) Industry, Company Share, 2014 15

Malaysia Polyethylene Terephthalate (PET) Industry, Market Dynamics, 2005-2019 16

Malaysia Polyethylene Terephthalate (PET) Industry, Market Size, 2005-2019 16

Malaysia Polyethylene Terephthalate (PET), Demand and Production Outlook, 2005-2019 18

Malaysia Polyethylene Terephthalate (PET) Industry, Demand by End Use Sector, 2014 20

Malaysia, Polyethylene Terephthalate (PET) Industry, Price Forecasts, 2005-2019 21

Malaysia Polyethylene Terephthalate (PET), Trade Balance, 2005-2019 23

Malaysia Polyethylene Terephthalate (PET) Industry, Imports and Exports, 2005-2019 23

Malaysia Polyethylene Terephthalate (PET) Industry, Net Exports, 2005-2019 25

Malaysia Polyethylene Terephthalate (PET) Industry, Imports as Percentage of Demand, 2005-2019 27

Reliance Industries Limited, Company Snapshot 29

Reliance Industries Limited, Company Overview 29

Reliance Industries Limited, Key Information 29

Reliance Industries Limited, Business Description 29

Business Overview 29

Oil and Gas 30

Organized Retail 30

Others 30

Petrochemicals 31

Refining 31

Reliance Industries Limited, Polyethylene Terephthalate (PET) Market, 2014 32

Reliance Industries Limited, Polyethylene Terephthalate (PET) Capacity Split, Malaysia and Rest of the World, 2014 32

Reliance Industries Limited, Polyethylene Terephthalate (PET) Plant Capacity Share in Malaysia, 2014 33

Reliance Industries Limited, Polyethylene Terephthalate (PET) Capacity in Malaysia, 2005-2019 34

Reliance Industries Limited, Polyethylene Terephthalate (PET) Plant Details in Malaysia, 2014 34

SWOT Analysis 35

Overview 35

Reliance Industries Limited Strengths 35

Reliance Industries Limited Weaknesses 36

Reliance Industries Limited Opportunities 36

Reliance Industries Limited Threats 37

MPI polyester Industries Sdn. Bhd. Ltd., Company Snapshot 39

MPI polyester Industries Sdn. Bhd. Ltd., Key Information 39

MPI polyester Industries Sdn. Bhd. Ltd., Polyethylene Terephthalate (PET) Market, 2014 40

MPI polyester Industries Sdn. Bhd. Ltd., Polyethylene Terephthalate (PET) Capacity Split, Malaysia and Rest of the World, 2014 40

MPI polyester Industries Sdn. Bhd. Ltd., Polyethylene Terephthalate (PET) Plant Capacity Share in Malaysia, 2014 40

MPI polyester Industries Sdn. Bhd. Ltd., Polyethylene Terephthalate (PET) Capacity in Malaysia, 2005-2019 41

MPI polyester Industries Sdn. Bhd. Ltd., Polyethylene Terephthalate (PET) Plant Details in Malaysia, 2014 41

Appendix 42

Definitions 42

Installed Plant Capacity 42

Process 42

Technology 42

Abbreviations 42

GlobalDatas Methodology 42

Coverage 42

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 44

Disclaimer 44

Source: http://www.researchbeam.com/polyethylene-terephthalate-pet-industry-outlook-in-malaysia-to-2019-size-company-share-price-trends-capacity-forecasts-of-all-active-and-planned-plants-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Chikungunya - Pipeline Review, H2 2015

Chikungunya Pipeline Review, H2 2015, provides an overview of the Chikungunyas therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chikungunya, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chikungunya and special features on late-stage and discontinued projects.

Enquiry about report: http://www.researchbeam.com/chikungunya-pipeline-review-h2-2015-market/enquire-about-report

Scope

The report provides a snapshot of the global therapeutic landscape of Chikungunya

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chikungunya and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chikungunya products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chikungunya pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

List of Tables

Number of Products under Development for Chikungunya, H2 2015 10

Number of Products under Development for Chikungunya - Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Development by Companies, H2 2015 (Contd...1) 14

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Comparative Analysis by Unknown Stage Development, H2 2015 18

Products under Development by Companies, H2 2015 19

Products under Development by Companies, H2 2015 (Contd...1) 20

Products under Investigation by Universities/Institutes, H2 2015 21

Chikungunya - Pipeline by Abivax S.A., H2 2015 22

Chikungunya - Pipeline by Arbovax, Inc., H2 2015 23

Chikungunya - Pipeline by Arno Therapeutics, Inc., H2 2015 24

Chikungunya - Pipeline by Bharat Biotech International Limited, H2 2015 25

Chikungunya - Pipeline by Etubics Corporation, H2 2015 26

Chikungunya - Pipeline by Indian Immunologicals Limited, H2 2015 27

Chikungunya - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 28

Chikungunya - Pipeline by Integral Molecular, Inc., H2 2015 29

Chikungunya - Pipeline by Merck & Co., Inc., H2 2015 30

Chikungunya - Pipeline by Nanotherapeutics, Inc., H2 2015 31

Chikungunya - Pipeline by PaxVax, H2 2015 32

Chikungunya - Pipeline by Profectus BioSciences, Inc., H2 2015 33

Chikungunya - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 34

Chikungunya - Pipeline by Themis Bioscience GmbH, H2 2015 35

Assessment by Monotherapy Products, H2 2015 36

Number of Products by Stage and Target, H2 2015 38

Number of Products by Stage and Mechanism of Action, H2 2015 40

Number of Products by Stage and Route of Administration, H2 2015 42

Number of Products by Stage and Molecule Type, H2 2015 44

Chikungunya Therapeutics - Recent Pipeline Updates, H2 2015 75

Chikungunya - Dormant Projects, H2 2015 78

 List of Figures

Number of Products under Development for Chikungunya, H2 2015 10

Number of Products under Development for Chikungunya - Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Products, H2 2015 17

Assessment by Monotherapy Products, H2 2015 36

Number of Products by Top 10 Targets, H2 2015 37

Number of Products by Stage and Top 10 Targets, H2 2015 37

Number of Products by Top 10 Mechanism of Actions, H2 2015 39

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 39

Number of Products by Routes of Administration, H2 2015 41

Number of Products by Stage and Routes of Administration, H2 2015 41

Number of Products by Top 10 Molecule Types, H2 2015 43

Number of Products by Stage and Top 10 Molecule Types, H2 2015 43

 Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chikungunya

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chikungunya pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Source: http://www.researchbeam.com/chikungunya-pipeline-review-h2-2015-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Chronic Urticaria Or Hives - Pipeline Review, H1 2015

Chronic Urticaria Or Hives - Pipeline Review, H1 2015, provides an overview of the Chronic Urticaria Or Hivess therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Urticaria Or Hives, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives and special features on late-stage and discontinued projects.

Enquiry about report: http://www.researchbeam.com/chronic-urticaria-or-hives-pipeline-review-h1-2015-market/enquire-about-report

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Chronic Urticaria Or Hives and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Chronic Urticaria Or Hives products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Chronic Urticaria Or Hives pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

List of Tables

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Chronic Urticaria Or Hives Overview 7

Therapeutics Development 8

Pipeline Products for Chronic Urticaria Or Hives - Overview 8

Pipeline Products for Chronic Urticaria Or Hives - Comparative Analysis 9

Chronic Urticaria Or Hives - Therapeutics under Development by Companies 10

Chronic Urticaria Or Hives - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Chronic Urticaria Or Hives - Products under Development by Companies 14

Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development 15

AstraZeneca PLC 15

Biofrontera AG 16

Bristol-Myers Squibb Company 17

ELORAC, Inc. 18

F. Hoffmann-La Roche Ltd. 19

FAES Farma SA 20

Genentech, Inc. 21

GlaxoSmithKline plc 22

Merck and Co., Inc. 23

Panacea Biotec Limited 24

Chronic Urticaria Or Hives - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

abatacept (recombinant) - Drug Profile 34

Product Description 34

Mechanism of Action 34

RandD Progress 34

AZD-1981 - Drug Profile 37

Product Description 37

Mechanism of Action 37

RandD Progress 37

BF-Derm-1 - Drug Profile 38

Product Description 38

Mechanism of Action 38

RandD Progress 38

bilastine - Drug Profile 39

Product Description 39

Mechanism of Action 39

RandD Progress 39

cidoxepin hydrochloride - Drug Profile 41

Product Description 41

Mechanism of Action 41

RandD Progress 41

desloratadine - Drug Profile 42

Product Description 42

Mechanism of Action 42

RandD Progress 42

GSK-2646264 - Drug Profile 43

Product Description 43

Mechanism of Action 43

RandD Progress 43

JDP-205 - Drug Profile 44

Product Description 44

Mechanism of Action 44

RandD Progress 44

omalizumab - Drug Profile 45

Product Description 45

Mechanism of Action 45

RandD Progress 45

omalizumab biosimilar - Drug Profile 47

Product Description 47

Mechanism of Action 47

RandD Progress 47

quilizumab - Drug Profile 48

Product Description 48

Mechanism of Action 48

RandD Progress 48

Chronic Urticaria Or Hives - Recent Pipeline Updates 49

Chronic Urticaria Or Hives - Dormant Projects 56

Chronic Urticaria Or Hives - Discontinued Products 57

Chronic Urticaria Or Hives - Product Development Milestones 58

Featured News and Press Releases 58

Aug 28, 2014: Novartis announces that Xolair is approved in Canada as a licensed therapy for chronic idiopathic urticaria (CIU) patients unresponsive to antihistamines 58

May 07, 2014: FDA Approves Xolair for Treatment of Chronic Hives 59

Mar 21, 2014: Novartis announces US FDA approval of Xolair for chronic idiopathic urticaria 59

Mar 06, 2014: Novartis announces Xolair approved in EU as first and only licensed therapy for chronic spontaneous urticaria patients unresponsive to antihistamines 60

Jan 24, 2014: Novartis reports positive opinion from CHMP for Xolair in severe form of skin disease CSU, a debilitating form of hives and chronic itch 62

Oct 11, 2013: FDA Files Genentechs Supplemental Biologics License Application of Xolair for Chronic Idiopathic Urticaria 64

Sep 30, 2013: Novartis to reveal landmark Phase III results of omalizumab at upcoming EADV 2013 congress 64

Jun 26, 2013: Novartis Reports New Phase III Data Showing Omalizumab Significantly Improves Itch In Patients With Severe Form Of CSU 66

Mar 20, 2013: Omalizumab Shows Promise In Eliminating Symptoms Of Chronic Urticaria, Study Finds 67

Feb 24, 2013: Genentech Reports Omalizumab Meets Primary Endpoint In Phase III Results In Patients With Chronic Form Of Hives Who Failed Standard Therapy 68

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

Source: http://www.researchbeam.com/chronic-urticaria-or-hives-pipeline-review-h1-2015-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Microalbuminuria Global Clinical Trials Review, H2, 2015

Microalbuminuria Global Clinical Trials Review, H2, 2015 provides an overview of Microalbuminuria clinical trials scenario. This report provides top line data relating to the clinical trials on Microalbuminuria. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7) , phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials) .

Enquiry about report: http://www.researchbeam.com/microalbuminuria-global-clinical-trials-review-h2-2015-market/enquire-about-report

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7) , Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

Table Of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Microalbuminuria 6

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Microalbuminuria to Genito Urinary System And Sex Hormones Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Microalbuminuria to Genito Urinary System And Sex Hormones Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Unaccomplished Trials of Microalbuminuria 25

Subjects Recruited Over a Period of Time 27

Clinical Trials by Sponsor Type 28

Prominent Sponsors 29

Top Companies Participating in Microalbuminuria Therapeutics Clinical Trials 30

Prominent Drugs 31

Clinical Trial Profiles 32

Clinical Trial Overview of Top Companies 32

Steno Diabetes Center A/S 32

Clinical Trial Overview of Steno Diabetes Center A/S 32

Novartis AG 33

Clinical Trial Overview of Novartis AG 33

Takeda Pharmaceutical Company Limited 34

Clinical Trial Overview of Takeda Pharmaceutical Company Limited 34

Sanofi 35

Clinical Trial Overview of Sanofi 35

Bristol-Myers Squibb Company 36

Clinical Trial Overview of Bristol-Myers Squibb Company 36

Alfa Wassermann S.p.A 37

Clinical Trial Overview of Alfa Wassermann S.p.A 37

Fondazione Mario Negri Sud 38

Clinical Trial Overview of Fondazione Mario Negri Sud 38

Daiichi Sankyo Company, Limited 39

Clinical Trial Overview of Daiichi Sankyo Company, Limited 39

AstraZeneca Plc 40

Clinical Trial Overview of AstraZeneca Plc 40

AbbVie Inc. 41

Clinical Trial Overview of AbbVie Inc. 41

Clinical Trial Overview of Top Institutes / Government 42

Hospital de Clinicas de Porto Alegre 42

Clinical Trial Overview of Hospital de Clinicas de Porto Alegre 42

Akershus University Hospital 43

Clinical Trial Overview of Akershus University Hospital 43

Asahikawa Medical College 44

Clinical Trial Overview of Asahikawa Medical College 44

Charles Drew University of Medicine and Science 45

Clinical Trial Overview of Charles Drew University of Medicine and Science 45

Chengdu University of Traditional Chinese Medicine 46

Clinical Trial Overview of Chengdu University of Traditional Chinese Medicine 46

Chiba University Hospital 47

Clinical Trial Overview of Chiba University Hospital 47

Chongqing Medical University (Inactive) 48

Clinical Trial Overview of Chongqing Medical University (Inactive) 48

Erasmus MC 49

Clinical Trial Overview of Erasmus MC 49

Gujarat Ayurved University 50

Clinical Trial Overview of Gujarat Ayurved University 50

Hospital Universitari Vall d'Hebron 51

Clinical Trial Overview of Hospital Universitari Vall d'Hebron 51

Five Key Clinical Profiles 52

Appendix 84

Abbreviations 84

Definitions 84

Research Methodology 85

Secondary Research 85

About GlobalData 86

Contact Us 86

Disclaimer 86

Source 87

Source: http://www.researchbeam.com/microalbuminuria-global-clinical-trials-review-h2-2015-market            

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Insulin Resistance Global Clinical Trials Review, H2, 2015

Insulin Resistance Global Clinical Trials Review, H2, 2015 provides an overview of Insulin Resistance clinical trials scenario. This report provides top line data relating to the clinical trials on Insulin Resistance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7) , phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials) . Clinical Trial Reports are generated using proprietary database Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Enquiry about report: http://www.researchbeam.com/insulin-resistance-global-clinical-trials-review-h2-2015-market/enquire-about-report

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7) , Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9

Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12

Top Countries Contributing to Clinical Trials in Central and South America 13

Clinical Trials by G7 Countries: Proportion of Insulin Resistance to Metabolic Disorders Clinical Trials 14

Clinical Trials by Phase in G7 Countries 15

Clinical Trials in G7 Countries by Trial Status 16

Clinical Trials by E7 Countries: Proportion of Insulin Resistance to Metabolic Disorders Clinical Trials 17

Clinical Trials by Phase in E7 Countries 18

Clinical Trials in E7 Countries by Trial Status 19

Clinical Trials by Phase 20

In Progress Trials by Phase 21

Clinical Trials by Trial Status 22

Clinical Trials by End Point Status 23

Subjects Recruited Over a Period of Time 24

Clinical Trials by Sponsor Type 25

Prominent Sponsors 26

Top Companies Participating in Insulin Resistance Therapeutics Clinical Trials 27

Prominent Drugs 28

Clinical Trial Profile Snapshots 29

Appendix 374

Abbreviations 374

Definitions 374

Research Methodology 375

Secondary Research 375

About GlobalData 376

Contact Us 376

Disclaimer 376

Source 377

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Source: http://www.researchbeam.com/insulin-resistance-global-clinical-trials-review-h2-2015-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Dental Biomaterials — Pipeline Review, 2015

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dental Biomaterials pipeline products.

Enquiry about report: http://www.researchbeam.com/dental-biomaterials-pipeline-review-2015-market/enquire-about-report

Table Of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 6

2 Introduction 7

2.1 Dental Biomaterials Overview 7

3 Products under Development 8

3.1 Dental Biomaterials - Pipeline Products by Stage of Development 8

3.2 Dental Biomaterials - Pipeline Products by Segment 9

3.3 Dental Biomaterials - Pipeline Products by Territory 10

3.4 Dental Biomaterials - Pipeline Products by Regulatory Path 11

3.5 Dental Biomaterials - Pipeline Products by Estimated Approval Date 12

3.6 Dental Biomaterials - Ongoing Clinical Trials 13

4 Dental Biomaterials - Pipeline Products under Development by Companies 14

4.1 Dental Biomaterials Companies - Pipeline Products by Stage of Development 14

4.2 Dental Biomaterials - Pipeline Products by Stage of Development 16

5 Dental Biomaterials Companies and Product Overview 18

5.1 3-D Matrix, Ltd. Company Overview 18

5.1.1 3-D Matrix, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 18

5.2 Advanced Medical Solutions Group plc Company Overview 20

5.2.1 Advanced Medical Solutions Group plc Pipeline Products & Ongoing Clinical Trials Overview 20

5.3 botiss dental GmbH Company Overview 28

5.3.1 botiss dental GmbH Pipeline Products & Ongoing Clinical Trials Overview 28

5.4 CollPlant Ltd. Company Overview 34

5.4.1 CollPlant Ltd. Pipeline Products & Ongoing Clinical Trials Overview 34

5.5 CoreBone Ltd. Company Overview 35

5.5.1 CoreBone Ltd. Pipeline Products & Ongoing Clinical Trials Overview 35

5.6 Harvard University Company Overview 36

5.6.1 Harvard University Pipeline Products & Ongoing Clinical Trials Overview 36

5.7 Histocell S.L. Company Overview 37

5.7.1 Histocell S.L. Pipeline Products & Ongoing Clinical Trials Overview 37

5.8 Ironwood Material Science Inc Company Overview 38

5.8.1 Ironwood Material Science Inc Pipeline Products & Ongoing Clinical Trials Overview 38

5.9 Lacerta Technologies GmbH Company Overview 39

5.9.1 Lacerta Technologies GmbH Pipeline Products & Ongoing Clinical Trials Overview 39

5.10 Maxigen Biotech Inc. Company Overview 40

5.10.1 Maxigen Biotech Inc. Pipeline Products & Ongoing Clinical Trials Overview 40

5.11 Medisse BV Company Overview 43

5.11.1 Medisse BV Pipeline Products & Ongoing Clinical Trials Overview 43

5.12 Medtronic plc Company Overview 44

5.12.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 44

5.13 Meta Biomed Co., Ltd. Company Overview 47

5.13.1 Meta Biomed Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 47

5.14 NDSU Research Foundation Company Overview 51

5.14.1 NDSU Research Foundation Pipeline Products & Ongoing Clinical Trials Overview 51

5.15 Noraker Company Overview 52

5.15.1 Noraker Pipeline Products & Ongoing Clinical Trials Overview 52

5.16 NovaBone Products, LLC. Company Overview 54

5.16.1 NovaBone Products, LLC. Pipeline Products & Ongoing Clinical Trials Overview 54

5.17 Novatissue SAS Company Overview 55

5.17.1 Novatissue SAS Pipeline Products & Ongoing Clinical Trials Overview 55

5.18 REGENECURE, Ltd. Company Overview 56

5.18.1 REGENECURE, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 56

5.19 Straumann Holding AG Company Overview 59

5.19.1 Straumann Holding AG Pipeline Products & Ongoing Clinical Trials Overview 59

5.20 SurgaColl Technologies Ltd Company Overview 62

5.20.1 SurgaColl Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 62

5.21 The University of Queensland Company Overview 63

5.21.1 The University of Queensland Pipeline Products & Ongoing Clinical Trials Overview 63

5.22 Tigran Technologies AB Company Overview 64

5.22.1 Tigran Technologies AB Pipeline Products & Ongoing Clinical Trials Overview 64

5.23 Universitat Politecnica de Catalunya Company Overview 65

5.23.1 Universitat Politecnica de Catalunya Pipeline Products & Ongoing Clinical Trials Overview 65

5.24 University of Strasbourg Company Overview 67

5.24.1 University of Strasbourg Pipeline Products & Ongoing Clinical Trials Overview 67

6 Dental Biomaterials- Recent Developments 68

7 Appendix 77

7.1 Methodology 77

7.2 About GlobalData 79

7.3 Contact Us 80

7.4 Disclaimer 80

Source: http://www.researchbeam.com/dental-biomaterials-pipeline-review-2015-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Slovenia Power Market Outlook to 2025, Update 2015 — Market Trends, Regulations, and Competitive Landscape

This report elaborates Slovenia™s power market structure and provides historical and forecast numbers for generation, capacity and consumption up to 2025. Detailed analysis of the Slovenia power market™s regulatory structure, import and export trends, competitive landscape and power projects at various stages of the supply chain is provided. The report also gives a snapshot of the power sector in Slovenia on broad parameters of macroeconomics, supply security, generation infrastructure, transmission infrastructure, degree of competition, regulatory scenario and future potential. Financial performance of the leading power companies is also analyzed in the report.

Enquiry about report: http://www.researchbeam.com/slovenia-power-outlook-to-2025-update-2015-trends-regulations-and-competitive-landscape-market/enquire-about-report

 Scope

Snapshot of the country™s power sector across parameters macro economics, supply security, generation infrastructure, transmission infrastructure, degree of competition, regulatory scenario and future potential of the power sector.

Statistics for installed capacity, power generation and consumption from 2000 to 2014, forecast for the next 11 years to 2025.

Break-up by technology, including thermal, hydro, renewable and nuclear

Data on leading current and upcoming projects.

Information on grid interconnectivity, transmission and distribution infrastructure and power exports and imports.

Policy and regulatory framework governing the market.

Detailed analysis of top market participant, including market share analysis and SWOT analysis.

Table of Content:

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 8

2 Introduction 9

2.1 GlobalData Report Guidance 10

3 Slovenia, Power Market, Snapshot 11

3.1 Slovenia, Power Market, Macro-economic Factors 11

3.2 Slovenia, Power Market, Supply Security 13

3.3 Slovenia, Power Market, Opportunities 14

3.4 Slovenia, Power Market, Challenges 15

4 Slovenia, Power Market, Market Analysis 16

4.1 Slovenia, Power Market, Supply Structure 16

4.1.1 Slovenia, Power Market, Key Market Players 16

4.2 Slovenia, Power Market, Financial Deals 18

4.2.1 Deal Volume and Value Analysis, 2004-June 2015 18

4.2.2 Deals by Type, 2014 19

4.3 Slovenia, Power Market, Demand Structure 19

4.3.1 Consumption by Sector, 2014 22

5 Slovenia, Power Market, Regulatory Scenario 23

5.1 Slovenia, Power Market, Market Liberalization Policies 23

5.2 Slovenia, Power Market, Energy Efficiency and Conservation Policies 23

5.3 Slovenia, Power Market, Renewable Energy Policies 24

5.3.1 Feed-in Tariff System 24

6 Slovenia, Power Market, Capacity and Generation Overview 27

6.1 Slovenia, Cumulative Installed Capacity by Fuel Type, 2014 27

6.2 Slovenia, Cumulative Installed Capacity and Annual Power Generation, 2000-2025 28

6.2.1 Cumulative Installed Thermal Capacity and Annual Thermal Power Generation, 2000-2025 31

6.2.2 Cumulative Installed Hydropower Capacity and Annual Hydropower Generation, 2000-2025 35

6.2.3 Cumulative Installed Nuclear Capacity and Annual Nuclear Power Generation, 2000-2025 38

6.2.4 Cumulative Installed Renewable Capacity and Annual Renewable Power Generation, 2000-2025 40

7 Slovenia, Power Market, Transmission and Distribution Overview 43

7.1 Slovenia, Power Market, Transmission Overview 43

7.2 Slovenia, Power Market, Distribution Overview 44

7.3 Slovenia, Power Market, Grid Interconnection 46

7.3.1 Electricity Import and Export Trends, 2000-2014 46

7.4 Slovenia, Power Market, Electricity Trading 48

8 Slovenia, Power Market, Competitive Landscape: Snapshot of Leading Power Generation Companies 50

8.1 Key Company in the Slovenia Power Market - Holding Slovenske elektrarne d.o.o. 50

8.1.1 Company Overview 50

8.1.2 Business Description 50

8.1.3 SWOT Overview 51

8.2 Key Company in the Slovenia Power Market - Gen energija, d.o.o. 54

8.2.1 Company Overview 54

8.2.2 Business Description 54

8.2.3 SWOT Overview 56

9 Appendix 59

9.1 Market Definitions 59

9.1.1 Power 59

9.1.2 Installed Capacity 59

9.1.3 Electricity Generation 59

9.1.4 Electricity Consumption 59

9.1.5 Thermal Power Plant 59

9.1.6 Hydropower Plant 59

9.1.7 Nuclear Power 59

9.1.8 Renewable Energy Resources 60

9.2 Abbreviations 61

9.3 Bibliography 62

9.4 GlobalData™s Methodology 62

9.4.1 Coverage 62

9.4.2 Secondary Research and Analysis 63

9.4.3 Primary Research and Analysis 63

9.5 Disclaimer 64

Source: http://www.researchbeam.com/slovenia-power-outlook-to-2025-update-2015-trends-regulations-and-competitive-landscape-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Iran Power Market Outlook to 2025, Update 2015 - Market Trends, Regulations, and Competitive Landscape

This report elaborates Iran's power market structure and provides historical and forecast numbers for generation, capacity and consumption up to 2025. Detailed analysis of the Iranian power markets regulatory structure, import and export trends, competitive landscape and power projects at various stages of the supply chain is provided. The report also gives a snapshot of the power sector in Iran on broad parameters of macroeconomics, supply security, generation infrastructure, transmission infrastructure, degree of competition, regulatory scenario and future potential. Financial performance of the leading power companies is also analyzed in the report.

Enquiry about report: http://www.researchbeam.com/iran-power-outlook-to-2025-update-2015-trends-regulations-and-competitive-landscape-market/enquire-about-report

Scope

Snapshot of the countrys power sector across parameters macro economics, supply security, generation infrastructure, transmission infrastructure, degree of competition, regulatory scenario and future potential of the power sector.

Statistics for installed capacity, power generation and consumption from 2000 to 2014, forecast for the next 11 years to 2025.

Break-up by technology, including thermal, hydro, renewable and nuclear

Data on leading current and upcoming projects.

Information on grid interconnectivity, transmission and distribution infrastructure and power exports and imports.

Policy and regulatory framework governing the market.

Detailed analysis of top market participant, including market share analysis and SWOT analysis.

Table of Content

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 9

2 Introduction 10

2.1 GlobalData Report Guidance 12

3 Iran, Power Market, Snapshot 13

3.1 Iran, Power Market, Macroeconomic Factors 13

3.2 Iran, Power Market, Supply Security 15

4 Iran, Power Market, Market Analysis 18

4.1 Iran, Power Market, Supply Structure 18

4.2 Iran, Power Market, Key Market Players 18

5 Iran, Power Market, Regulatory Scenario 24

5.1 Iran, Power Market, Key Electricity Policies 24

5.2 Iran, Renewable Power Policy 26

6 Iran, Power Market, Capacity and Generation Overview 29

6.1 Iran, Power Market, Cumulative Installed Capacity by Fuel Type, 2014 29

6.2 Iran, Power Market, Cumulative Installed Capacity and Annual Power Generation, 2000 - 2025 30

7 Iran, Power Market, Transmission and Distribution Overview 47

7.1 Iran, Power Market, Transmission Overview 47

7.2 Iran, Power Market, Distribution Overview 48

8 Iran, Power Market, Competitive Landscape: Snapshot of Leading Power Generating Companies 52

8.1 Key Company in the Iran Power Market: Tavanir 52

9 Appendix 57

9.1 Market Definitions 57

9.2 Abbreviations 58

Source: http://www.researchbeam.com/iran-power-outlook-to-2025-update-2015-trends-regulations-and-competitive-landscape-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

[danrobertsonrb-blog]

Metabolite Chemistry Reagents Pipeline Review, 2015

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Metabolite Chemistry Reagents pipeline products.

Enquiry about report: http://www.researchbeam.com/metabolite-chemistry-reagents-pipeline-review-2015-market/enquire-about-report

 Scope

Extensive coverage of the Metabolite Chemistry Reagents under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Metabolite Chemistry Reagents and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

 Table of Content

1 Table of Contents 2

2 Introduction 8

3 Products under Development 9 Approval Date 12

4 Metabolite Chemistry Reagents - Pipeline Products under Development by Companies 14

5 Metabolite Chemistry Reagents Companies and Product Overview 18

6 Metabolite Chemistry Reagents- Recent Developments 81

7 Appendix 86

Reasons to buy

The report enables you to

Formulate significant competitor information, analysis, and insights to improve R & D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Metabolite Chemistry Reagents under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the products current stage of development, territory and estimated launch date

 Source: http://www.researchbeam.com/metabolite-chemistry-reagents-pipeline-review-2015-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam